Edgewise Therapeutics stock rose 2.18% on Tuesday after JPMorgan analyst Tessa Romero raised her price target by $11 per share to $45, maintaining an overweight rating. The upgrade was driven by optimism about the company's pipeline drugs, particularly EDG-7500 for heart disorder treatment and sevasemten for muscular dystrophy, which showed positive long-term study data.

Edgewise Therapeutics, a $3.1B biotech company, has two major drug candidates with significant market potential. EDG-7500 for hypertrophic cardiomyopathy uses a novel mechanism (promoting heart relaxation) with superior safety profile compared to existing treatments, with efficacy data expected by June 2026. Sevasemten targets Becker Muscular Dystrophy, a disease with zero approved treatments, with pivotal trial results expected Q4 2026. The stock has tripled from its 52-week low and faces two binary catalysts this year.

Edgewise Therapeutics stock surged 4% on Monday after analyst Yasmeen Rahimi from Piper Sandler reiterated an overweight recommendation with a $51 price target. Rahimi flagged the biotech as one of Piper Sandler's best stock ideas for 2026, citing strong potential for its lead cardiovascular drug candidate EDG-7500 for treating hypertrophic cardiomyopathy, with Phase 2 results expected in Q2 2026. The company also has other promising pipeline programs including Sevasemten for muscular dystrophy.

Edgewise Therapeutics stock surged nearly 26% on December 23rd after the biotech presented positive interim Phase 2 clinical trial data for EDG-7500, an investigational drug targeting hypertrophic cardiomyopathy (HCM). The drug showed clinical activity across significant disease markers, maintained a favorable safety profile, and exceeded year-end enrollment goals with over 70% of participants reaching the target 100mg dose. However, the author notes the drug still has distance to go before potential regulatory approval.

Pomerantz Law Firm is investigating potential securities fraud by Edgewise Therapeutics after the company reported clinical trial results that were deemed insufficient for accelerated FDA approval, causing a stock price drop.

Pomerantz Law Firm is investigating potential securities fraud at Edgewise Therapeutics after the company reported clinical trial results that were deemed insufficient for accelerated FDA approval, causing a stock price drop.

Edgewise Therapeutics' (EWTX) share price surged 50% in a single session due to positive results from early trials of its novel treatment for obstructive hypertrophic cardiomyopathy, a leading cause of sudden cardiac-related death in young people. The company's pipeline and strong financial position also contribute to the positive sentiment.

Bausch & Lomb and Edgewise Therapeutics were among the top 7 mid-cap stock gainers last week, with Edgewise Therapeutics shares rocketing 50.19% after announcing positive topline data from a clinical trial, and Bausch & Lomb's parent company Bausch Health considering a sale.

Edgewise Therapeutics' cardiac drug EDG-7500 shows promise in clinical trials for treating obstructive hypertrophic cardiomyopathy, a condition marked by thickening of the left heart ventricle wall. The drug was well-tolerated and did not lead to lowered left ventricular ejection fraction levels, a common issue with other cardiac drugs. However, any potential commercialization is still years away.

The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Tile Shop The Trade: Tile Shop Holdings, Inc. (NASDAQ: TTSH) 10% owner Pleasant Lake Partners LLC